Still struggling with its "go it alone" strategy, ThromboGenics has cut back its EU workforce in order to pursue lead product Jetrea in the US.
Back in June, the Belgian biotechnology company said that, contrary to analysts' expectations, it was not about to be sold...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?